21 Mar 2022 10:02
21 March 2022
Clinigen Group plc
Block Listing Application
Clinigen Group plc (AIM: CLIN) ('Clinigen' or the 'Company' or the 'Group'), the global pharmaceutical Services and Products company, announces that a block listing application has been made to the London Stock Exchange for 3,000,000 ordinary shares of 0.1 pence each ("Ordinary Shares") to be admitted to trading on AIM (the "Admission"). The Ordinary Shares that are being reserved under this block listing application will be issued by the Company, as required, in order to satisfy the exercise of share options pursuant to the terms of its share plans, including on or after the Court sanction of the proposed scheme of arrangement for the Company in connection with the acquisition of the Company by Triley Bidco Limited, which is scheduled to be heard on 31 March 2022.
It is expected that Admission of these Ordinary Shares will become effective on 23 March 2022. When issued, the Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares.
For more information, please contact:
Clinigen Group plc | +44 (0) 1283 495010 |
Shaun Chilton, Chief Executive Officer Richard Paling, Interim Chief Financial Officer Rob Fox, VP Investor Relations and Corporate Development | investors@clinigengroup.com |
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Garry Levin / Freddie Barnfield | Clinigen@Numis.com
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Hodgson |
Tel: +44 (0) 20 3709 5700 Clinigen@consilium-comms.com
|
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its' mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 20,000 healthcare professionals across more than 120 countries.
For more information on Clinigen, please visit http://www.clinigen.com